Pharmacokinetic similarity of switching <scp>SAR341402</scp> insulin aspart biosimilar and <scp>NovoLog</scp> insulin aspart versus continuous use of <scp>NovoLog</scp> in adults with type 1 diabetes: The <scp>GEMELLI</scp> X trial

20233 citationsJournal Articlehybrid Open Access

Authors

Viral N. Shah · University of Colorado Anschutz Medical Campus

Amer Al‐Karadsheh

Cathy Barnes · Suncoast Clinical Research

Jose Mandry

Samer Nakhle

Karin Wernicke‐Panten · Sanofi (Germany)

Daniel Kramer · Sanofi (Germany)

Wolfgang Schmider · Sanofi (Germany)

Abstract

PK exposure of SAR-Asp (switching group) and reference NN-Asp (non-switching group) were similar, supporting interchangeability between these two insulin aspart products.

Topics & Keywords

Pharmaceutical studies and practices Diabetes Management and Research Biosimilars and Bioanalytical Methods

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 26, Issue 2, pp. 540-547

DOI: 10.1111/dom.15341

Field-Weighted Citation Impact: 1.78